DDIT4L antisense RNA 1 (DDIT4L-AS1)

DDIT4L antisense RNA 1 (DDIT4L-AS1) is a **long non-coding antisense RNA** located on chromosome 4, transcribed from the opposite strand of the DDIT4L gene[1][10]. It is functionally characterized as a cytoplasmic antisense lncRNA that modulates the stability of DDIT4L mRNA by forming an RNA duplex, thereby positively regulating DDIT4L expression[2][3]. DDIT4L-AS1 has been implicated in the regulation of **neuroinflammation**, particularly in **bacterial meningitis** by enhancing inflammatory signals through DDIT4 pathway stabilization, notably affecting NF-κB signaling and pro-inflammatory cytokine expression[2][3]. Additionally, it acts as an **oncogenic lncRNA** in **triple-negative breast cancer**, promoting tumor cell proliferation and migration, and contributing to chemoresistance by activating autophagy; silencing DDIT4L-AS1 sensitizes tumors to paclitaxel[5]. As an antisense lncRNA, DDIT4L-AS1 is not a protein receptor, enzyme, or transporter but is considered a therapeutic target at the nucleic acid level for disease intervention and biomarker development[5].

Other names

DDIT4L-AS1DNA damage inducible transcript 4 antisense RNA 1RP11-442H21.2

No direct-acting small molecule or classic therapeutic drugs targeting DDIT4L-AS1 are currently listed; however, silencing (by siRNA) leads to downregulation of autophagy and increased chemotherapy sensitivity[5].